Innovation in Cancer Treatment: Pushing for Localization of Next-Generation Radioisotope 'Actinium-225'
The localization of 'Actinium-225,' a radioisotope known to be the most potent agent in recent cancer treatment, is being pursued in earnest. Actinium-225 is a key material for 'targeted alpha therapy,' which precisely identifies and destroys only cancer cells, and it is a next-generation pharmaceutical raw material for which global demand is surging.
Currently, there is a global shortage of Actinium-225. Due to a high reliance on imports, domestic medical facilities have faced difficulties in securing a stable supply of the treatment. In response, the government and relevant research institutions have established a plan to produce this material directly using domestic technology to provide cancer patients with faster and more stable treatment opportunities.
If this localization project succeeds, South Korea will establish its own production system instead of importing expensive radiopharmaceuticals. This is expected to not only lower the cost of cancer treatment but also significantly contribute to enhancing the competitiveness of the domestic bio-industry. Experts evaluate this technological development as an important turning point that will shift the paradigm of cancer treatment.
If related research proceeds without setbacks, domestic cancer patients will be able to access more advanced treatments more easily. The government has stated that it will spare no support for the technology development and plans to strive for the improvement of public health by building a stable supply chain in the future.